Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Africa Vaccine Supplies To Rise After ‘Worst Pandemic Week Ever’

UNICEF Signs Delivery Deal For Janssen COVID-19 Vaccine

Executive Summary

Despite an alarming surge in coronavirus cases across the African continent, there are hopes of a substantial rise in vaccine supplies in the coming months.

You may also be interested in...



Coronavirus Notebook: WHO Adds More Drugs To Solidarity Trial, COVAX Ups Vaccine Supplies To Africa

The Coalition for Epidemic Preparedness and Innovations is working with China’s ZerunBio to develop prototype and variant vaccine candidates, and Australia believes MSD’s molnupiravir could be a potential treatment for COVID-19. The European Medicines Agency is looking into more possible side effects with two mRNA vaccines. 

Coronavirus Notebook: Vaccine Safety Study Kicks Off In UK, Govt Plans Booster Vaccination For Most Vulnerable

A new international task force has used its first meeting to call for more access to COVID-19 vaccines and therapies in developing countries, and the World Bank and other finance institutions are putting money into South African firm Aspen Pharmacare to boost the production of vaccines.

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel